Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Single Protein Encapsulated Doxorubicin for the Treatment of Advanced, Refractory or Relapsed Solid Tumor Malignancies

Trial Status: active

This phase I/II trial tests the safety, side effects and best dose of single protein encapsulated doxorubicin (SPEDOX-6) for the treatment of patients with solid tumor malignancies that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), that have not responded to previous treatment (refractory) or that have come back after a period of improvement (relapsed). SPEDOX-6 is a special form of a chemotherapy called doxorubicin that is designed to target cancer cells more precisely, particularly those that have low levels of a specific protein called the neonatal Fc receptor (FcRn). This protein is important because it helps protect certain molecules in the body from being broken down too quickly and is involved in the immune system's ability to fight disease.